Harvest Portfolios Group
Latest Top Picks
https://www.pmlive.com/pharma_news/fda_sets_november_date_for_expert_panel_review_of_biogens_aducanumab_1351831 Until February 2020, Biogen's FDA results of an Alzheimer drug was the healthcare event of the year (then Covid hit). Novartis and other players are starting to compete here, though. He owned Biogen some years ago. He was on a panel which was split over whether Biogen would get FDA approval on Nov. 6. Regardless, this is a high-risk play; this could pop 35-50% up or down. The risk/return is too much for him. The drug has a checkered past and so far there is no effective Alzheimer's drug, but if it works it will be huge for the company and society.
https://www.pmlive.com/pharma_news/fda_sets_november_date_for_expert_panel_review_of_biogens_aducanumab_1351831 Until February 2020, Biogen's FDA results of an Alzheimer drug was the healthcare event of the year (then Covid hit). Novartis and other players are starting to compete here, though. He owned Biogen some years ago. He was on a panel which was split over whether Biogen would get FDA approval on Nov. 6. Regardless, this is a high-risk play; this could pop 35-50% up or down. The risk/return is too much for him. The drug has a checkered past and so far there is no effective Alzheimer's drug, but if it works it will be huge for the company and society.
It's focused 90% in diabetes products which offers a competitive advantage. He owned this before, but sold it because its options liquidity is low in the US (he trades options). Instead, he owns its direct competitor, Eli Lily, which boasts more product diversity. (Both companies have phase 3 Covid drugs.) Novo is a leader in diabetes and good to own unless you trade options.
It's focused 90% in diabetes products which offers a competitive advantage. He owned this before, but sold it because its options liquidity is low in the US (he trades options). Instead, he owns its direct competitor, Eli Lily, which boasts more product diversity. (Both companies have phase 3 Covid drugs.) Novo is a leader in diabetes and good to own unless you trade options.
Disclosure: He runs this ETF, 20 equally-weighted large US healthcare stocks. He makes minor adjustments periodically, like selling Gilead recently. He wants diversification across this space. Pays a high dividend, using covered calls for a third of the holdings. This is good if you want US healthcare and regular income with some appreciation.
Disclosure: He runs this ETF, 20 equally-weighted large US healthcare stocks. He makes minor adjustments periodically, like selling Gilead recently. He wants diversification across this space. Pays a high dividend, using covered calls for a third of the holdings. This is good if you want US healthcare and regular income with some appreciation.
Their Covid vaccine in progress For most of the large-cap pharmas he owns, the benefits of producing this vaccine won't benefit these companies as much as people think. That said, AZN has been executing very well in areas like oncology--a key driver for them. In May, AZN's vaccine was his front runner in this race. AZN (with Oxford University) did have a negative reaction during their recent phase 3 test, though, so there is a risk here. However AZN has resumed tests outside the U.S., so expect results a little later. So now Pfizer has become the front runner. He's looking for the safety profile of AZN's candidate. If their vaccine is a miss, there will be stock volatility, but also a buying opportunity. A great company.
Their Covid vaccine in progress For most of the large-cap pharmas he owns, the benefits of producing this vaccine won't benefit these companies as much as people think. That said, AZN has been executing very well in areas like oncology--a key driver for them. In May, AZN's vaccine was his front runner in this race. AZN (with Oxford University) did have a negative reaction during their recent phase 3 test, though, so there is a risk here. However AZN has resumed tests outside the U.S., so expect results a little later. So now Pfizer has become the front runner. He's looking for the safety profile of AZN's candidate. If their vaccine is a miss, there will be stock volatility, but also a buying opportunity. A great company.
He liked their Celgene acquisition last year (though the market didn't), because it diversified their exposure to other drugs which have exectued well. Their R&D and core business are doing well. The stock trades at only 8x earnings. There is a disconnect between company performance and the market. It's very cheap and they execute well. (Analysts’ price target is $72.93)
He liked their Celgene acquisition last year (though the market didn't), because it diversified their exposure to other drugs which have exectued well. Their R&D and core business are doing well. The stock trades at only 8x earnings. There is a disconnect between company performance and the market. It's very cheap and they execute well. (Analysts’ price target is $72.93)
